Expression patterns of lymphangiogenic and angiogenic factors in a model of breast ductal carcinoma in situ

American Journal of Surgery

Volumn 194, Issue 5, 2007, Pages 594-599

  Yu, Minghuan ^a   Tang, Zhuo ^b   Alousi, Sarah ^a   Berk, Richard S ^b   Miller, Fred ^c   Kosir, Mary Ann ^a,c,d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ductal carcinoma in situ; Lymphangiogenesis; Vascular endothelial growth factor D

Indexed keywords

ANGIOGENIC FACTOR; BETA ACTIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR 1; MATRIGEL; UNCLASSIFIED DRUG; VASCULOTROPIN D;

ARTICLE; BREAST CARCINOMA; BREAST DUCT; CANCER CELL CULTURE; CANCER INVASION; CARCINOMA IN SITU; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPHANGIOGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOGENESIS INDUCING AGENTS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VESICULAR TRANSPORT PROTEINS;

EID: 35148846293     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2007.08.007     Document Type: Article

References (25)

1. Cody H.S. Sentinel lymph node biopsy for DCIS: Are we approaching consensus?. Ann Surg Oncol 14 (2007) 2178-2181
2. Maffuz A., Barroso-Bravo S., Najera I., et al. Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ. J Exp Clin Cancer Res 25 (2006) 223-227
3. Yen T.W., Hunt K.K., Ross M.I., et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 200 (2005) 516-526
4. Tan J.C.C., McCready D.R., Easson A.M., et al. Role of sentinel lymph node biopsy inductal carcinoma-in-situ treated by mastectomy. Ann Surg Oncol 14 (2006) 638-645
5. Tait L.R., Pauley R.J., Santner S.J., et al. Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts. Int J Cancer 120 (2007) 2127-2134
6. Miller F.R., Soule H.D., Tait L., et al. Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 85 (1993) 1725-1732
7. Arpino G., Laucirica R., and Elledge R.M. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 143 (2005) 446-457
8. Leonard G.D., and Swain S.M. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96 (2004) 906-920
9. Achen M.G., Mann G.B., and Sacher S.A. Targeting lymphangiogenesis to prevent tumor metastasis. Br J Cancer 94 (2006) 1355-1360
10. Julian T, Fourchotte V, Anderson S, et al. Predictive factors that identify patients not requiring a sentinel node biopsy: continued analysis of the NSABP B-32 sentinel node trial. Poster presented at: San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX.
11. Nakamura Y., Yasuoka H., Tsujimoto, et al. Flt-4-positive vessel density correlates with vascular endothelial growth factor-D expression, nodal status, and prognosis in breast cancer. Clin Cancer Res 9 (2003) 5313-5317
12. Wolfing P., Kersting C., Buerger H., et al. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer 92 (2005) 1720-1728
13. Gotte M., Kersting C., Radke I., et al. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 9 (2007) R8 (doi;10.1186/bcr1641)
14. Miller F.R., Santner S.J., Tait L., and Dawson P.J. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 92 (2000) 1185-1186
15. Miller F.R. Xenograft models of premalignant breast disease. J Mam Gland Biol Neoplasia 5 (2000) 379-391
16. Jeltsch M., Kaipainen A., Joukov V., et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276 (1997) 1423-1425
17. Stacker S.A., Caesar C., Baldwin M.E., et al. VEGF-D promotes the metastatic spread oftumor cells via the lymphatics. Nat Med 7 (2001) 186-191
18. Kaipainen A., Korhonen J., Mustonen T., et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 92 (1995) 3566-3570
19. Valtaola R., Salven P., Heikkila P., et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154 (1999) 1381-1390
20. Kitadai Y., Kodama M., Cho S., et al. Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes. Int J Cancer 115 (2005) 388-392
21. Banerji S., Ni J., Wang S.X., et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 144 (1999) 789-801
22. Skobe M., Hawighorst T., Jackson D.G., et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7 (2001) 192-198
23. Mouta Carreira C., Nasser S.M., di Tomaso E., et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 61 (2001) 8079-8084
24. Chen L., Cursiefen C., Barabino S., et al. Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells. Invest Ophthalmol Vis Sci 46 (2005) 4536-4540
25. Lee J.Y., and Spicer A.P. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol 12 (2000) 581-586